FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078287464> ?p ?o ?g. }

• W2078287464 endingPage "1465" @default.
• W2078287464 startingPage "1459" @default.
• W2078287464 abstract "Raloxifene use in postmenopausal women with osteoporosis increases the risk of venous thromboembolic events (VTE) 2-fold compared with placebo. Platelet activation is involved in the pathophysiology of arterial thromboses more than venous thromboses, but aspirin may reduce VTE risk associated with estrogen use. This analysis examines the effects of concomitant antiplatelet therapy on VTE risk in raloxifene-treated women.In the Raloxifene Use for the Heart (RUTH) trial, 10,101 postmenopausal women from 177 sites in 26 countries at increased risk of coronary heart disease (CHD) (primary prevention cohort) or with CHD (secondary prevention cohort) were randomized to placebo or raloxifene 60 mg/day and followed for a median 5.6 years. Reports of clinical symptoms of VTE were assessed. Concomitant use of antiplatelet agents (aspirin, clopidogrel, ticlopidine, dipyridamole) was allowed. Cox proportional hazard models, with use of warfarin, presence of fracture, and hospitalization as covariates, were used to estimate hazard ratios (HR) with 95% confidence intervals (CI).Overall, raloxifene use was associated with an increased VTE risk (HR 1.44, 95% CI 1.06-1.95) vs. placebo. Most women (72%) reported using aspirin, and 14.2% reported using nonaspirin antiplatelet agents during the study period. Users of antiplatelet agents were older, more likely to have CHD, and more likely to be hyperlipidemic. They had a higher VTE risk than nonusers. No difference in VTE risk was observed in women who used raloxifene alone vs. those who used raloxifene with antiplatelet agents during the study. The increase in VTE risk with raloxifene compared with placebo was not different between women who used antiplatelet agents at baseline (HR 1.44, 95% CI 0.98, 2.10) and those who did not use antiplatelet agents (HR 1.37, 95% CI 0.83, 2.27) (interaction p = 0.88). Similar conclusions were noted for aspirin and nonaspirin antiplatelet use.In RUTH, postmenopausal women treated with raloxifene had an increased risk of VTE compared with placebo. Concomitant use of aspirin or nonaspirin antiplatelet agents along with raloxifene did not change VTE risk." @default.
• W2078287464 created "2016-06-24" @default.
• W2078287464 creator A5001789798 @default.
• W2078287464 creator A5010849446 @default.
• W2078287464 creator A5011582505 @default.
• W2078287464 creator A5014043242 @default.
• W2078287464 creator A5072644098 @default.
• W2078287464 date "2010-08-01" @default.
• W2078287464 modified "2023-09-26" @default.
• W2078287464 title "Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Raloxifene Use for the Heart (RUTH) Trial" @default.
• W2078287464 cites W1593008417 @default.
• W2078287464 cites W1978335872 @default.
• W2078287464 cites W2003019536 @default.
• W2078287464 cites W2008660261 @default.
• W2078287464 cites W2048257551 @default.
• W2078287464 cites W2049042206 @default.
• W2078287464 cites W2064851078 @default.
• W2078287464 cites W2073031659 @default.
• W2078287464 cites W2092397820 @default.
• W2078287464 cites W2113264115 @default.
• W2078287464 cites W2125813680 @default.
• W2078287464 cites W2126595069 @default.
• W2078287464 cites W2141647078 @default.
• W2078287464 cites W2161735825 @default.
• W2078287464 cites W2172185687 @default.
• W2078287464 cites W2258503797 @default.
• W2078287464 cites W2349457619 @default.
• W2078287464 cites W4230017930 @default.
• W2078287464 cites W4239471829 @default.
• W2078287464 cites W4248039657 @default.
• W2078287464 cites W4251833922 @default.
• W2078287464 doi "https://doi.org/10.1089/jwh.2009.1687" @default.
• W2078287464 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20626269" @default.
• W2078287464 hasPublicationYear "2010" @default.
• W2078287464 type Work @default.
• W2078287464 sameAs 2078287464 @default.
• W2078287464 citedByCount "12" @default.
• W2078287464 countsByYear W20782874642012 @default.
• W2078287464 countsByYear W20782874642013 @default.
• W2078287464 countsByYear W20782874642014 @default.
• W2078287464 countsByYear W20782874642016 @default.
• W2078287464 countsByYear W20782874642018 @default.
• W2078287464 countsByYear W20782874642019 @default.
• W2078287464 countsByYear W20782874642020 @default.
• W2078287464 countsByYear W20782874642023 @default.
• W2078287464 crossrefType "journal-article" @default.
• W2078287464 hasAuthorship W2078287464A5001789798 @default.
• W2078287464 hasAuthorship W2078287464A5010849446 @default.
• W2078287464 hasAuthorship W2078287464A5011582505 @default.
• W2078287464 hasAuthorship W2078287464A5014043242 @default.
• W2078287464 hasAuthorship W2078287464A5072644098 @default.
• W2078287464 hasBestOaLocation W20782874642 @default.
• W2078287464 hasConcept C121608353 @default.
• W2078287464 hasConcept C126322002 @default.
• W2078287464 hasConcept C142724271 @default.
• W2078287464 hasConcept C204787440 @default.
• W2078287464 hasConcept C207103383 @default.
• W2078287464 hasConcept C27081682 @default.
• W2078287464 hasConcept C2776301958 @default.
• W2078287464 hasConcept C2776541429 @default.
• W2078287464 hasConcept C2777176818 @default.
• W2078287464 hasConcept C2777628954 @default.
• W2078287464 hasConcept C2779161974 @default.
• W2078287464 hasConcept C2779889926 @default.
• W2078287464 hasConcept C44249647 @default.
• W2078287464 hasConcept C530470458 @default.
• W2078287464 hasConcept C71924100 @default.
• W2078287464 hasConceptScore W2078287464C121608353 @default.
• W2078287464 hasConceptScore W2078287464C126322002 @default.
• W2078287464 hasConceptScore W2078287464C142724271 @default.
• W2078287464 hasConceptScore W2078287464C204787440 @default.
• W2078287464 hasConceptScore W2078287464C207103383 @default.
• W2078287464 hasConceptScore W2078287464C27081682 @default.
• W2078287464 hasConceptScore W2078287464C2776301958 @default.
• W2078287464 hasConceptScore W2078287464C2776541429 @default.
• W2078287464 hasConceptScore W2078287464C2777176818 @default.
• W2078287464 hasConceptScore W2078287464C2777628954 @default.
• W2078287464 hasConceptScore W2078287464C2779161974 @default.
• W2078287464 hasConceptScore W2078287464C2779889926 @default.
• W2078287464 hasConceptScore W2078287464C44249647 @default.
• W2078287464 hasConceptScore W2078287464C530470458 @default.
• W2078287464 hasConceptScore W2078287464C71924100 @default.
• W2078287464 hasIssue "8" @default.
• W2078287464 hasLocation W20782874641 @default.
• W2078287464 hasLocation W20782874642 @default.
• W2078287464 hasLocation W20782874643 @default.
• W2078287464 hasOpenAccess W2078287464 @default.
• W2078287464 hasPrimaryLocation W20782874641 @default.
• W2078287464 hasRelatedWork W2014876946 @default.
• W2078287464 hasRelatedWork W2037421482 @default.
• W2078287464 hasRelatedWork W2070235427 @default.
• W2078287464 hasRelatedWork W2102355502 @default.
• W2078287464 hasRelatedWork W2119935488 @default.
• W2078287464 hasRelatedWork W2346101032 @default.
• W2078287464 hasRelatedWork W2363355541 @default.
• W2078287464 hasRelatedWork W2405677756 @default.
• W2078287464 hasRelatedWork W2408450845 @default.
• W2078287464 hasRelatedWork W4301683752 @default.

• next